Blair William & Co. IL Has $28.88 Million Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Blair William & Co. IL cut its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,261,677 shares of the biopharmaceutical company's stock after selling 89,031 shares during the period. Blair William & Co. IL owned approximately 1.72% of Dynavax Technologies worth $28,882,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DVAX. Smartleaf Asset Management LLC increased its holdings in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC grew its position in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at about $71,000. Nisa Investment Advisors LLC lifted its stake in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the period. Finally, KBC Group NV grew its position in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 2,857 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

DVAX has been the subject of a number of research reports. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Price Performance

DVAX traded down $0.05 during trading on Tuesday, hitting $12.93. The company's stock had a trading volume of 443,535 shares, compared to its average volume of 2,163,425. The firm's 50 day moving average price is $13.36 and its two-hundred day moving average price is $12.52. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of 71.81 and a beta of 1.23. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.